Suppliers and packagers for SAMSCA

SAMSCA (tolvaptan) suppliers: API, contract manufacturing, and key distribution partners

Executive summary: Suppliers for SAMSCA (tolvaptan) break into three practical buckets for sourcing and risk analysis: (1) API/active ingredient manufacturers, (2) finished-dose and packaging contract manufacturers for tolvaptan tablets, and (3) authorized distributors that carry branded product into the US channel. The supplier map depends on whether you need commercial tablets, clinical supply, API, or bulk/finished goods for regulated markets.

Who supplies SAMSCA (tolvaptan) in the US distribution channel?

Short answer: SAMSCA is marketed as a branded product in the US through the manufacturer’s supply chain and authorized distributors. Channel suppliers are typically organized through wholesalers and distribution networks rather than public, named contract partners for each lot.

Authorized wholesaler/distributor layer

• US supply is typically routed through large pharmaceutical wholesalers that warehouse and distribute branded hospital and specialty drugs.
• For procurement planning, the relevant “supplier” is often the wholesaler/broker of record for your purchasing lane (GPO, hospital contract, specialty pharmacy fulfillment, or direct buy through distributor).

What to check for supplier onboarding

• NDC-specific inventory provenance (manufacturer labeler on the NDC listing)
• Traceability documentation in the receiving package (COA, lot/batch trace)
• Whether the buying entity is sourcing FDA-registered supply chain nodes for GDP compliance

Who makes tolvaptan API for SAMSCA?

Short answer: Tolvaptan API suppliers are generally disclosed through DMF references, FDA registration listings, and supplier/partner disclosures tied to the approved NDA and commercial manufacturing network. For branded commercial drugs, API manufacture can be split across multiple registered sites to support supply continuity.

API sourcing signals used in practice

• FDA Drug Master File (DMF) holders cited by the NDA for tolvaptan substance
• API manufacturing site registrations in FDA’s drug establishment data
• Quality agreement and site-specific COA matching for incoming batches

How many API sources are typically used

• Most small-molecule branded products use multiple API sites or at least backup synthesis routes once commercial volume ramps.
• For sourcing risk controls, companies usually qualify two independent sources or a primary source plus a fast-switch alternate under change control.

Which companies manufacture SAMSCA tolvaptan tablets (finished dose)?

Short answer: Finished-dose manufacturers for SAMSCA are identifiable through the approved product’s manufacturing and packaging site listings and (where available) public filings tied to the NDA. Contract manufacturers are common even when marketing is under the brand holder.

Finished-dose manufacturing layers

• Tablet manufacturing: blending, granulation, compression, and tablet coating
• Packaging: bottle filling, labeling, case packing, and serialization (if applicable)

Common site roles you will see in listings

• Manufacturing site (tablet production)
• Packaging site (bottle/carton operations)
• Quality/testing site (often integrated or co-located)

What packaging suppliers support SAMSCA (bottles, cartons, labeling)?

Short answer: Packaging suppliers are typically the packagers of record for the NDC. They may be separate registered sites from tablet manufacturing to support line capacity and packaging specialization.

Packaging-critical checkpoints

• Bottle material and tamper evidence compatibility with GMP
• Labeling compliance: NDC accuracy, lot number printing, and regulatory wording
• Serialization and track-and-trace capability for market requirements

What is the supplier landscape for SAMSCA in clinical or hospital procurement?

Short answer: Clinical/hospital supply is usually delivered by the same branded supply chain but supported by lot releases and distribution partners that satisfy institutional procurement terms.

Procurement-specific supplier behavior

• Hospitals commonly buy through authorized wholesalers aligned to the hospital’s contract structure.
• Clinical sites may receive supply through:
  • distribution partners under the NDA supply chain
  • or direct fulfillment from the brand holder for investigator-led uses

How to identify SAMSCA’s true manufacturing and packaging supplier for a given lot?

Short answer: The supplier you need for lot-level decisions is identified by lot-traceable documentation and the establishment/labeler data tied to the NDC.

Lot-level checks (actionable)

• Confirm the labeled manufacturer/packager on the carton and bottle
• Match the lot number to:
  • COA batch identity
  • UDI/GTIN labeling if present
  • distribution documentation from the receiving node

Which risks matter when sourcing SAMSCA from alternative suppliers?

Short answer: The main sourcing risks are regulatory and supply-chain provenance, not just price. Tolvaptan has a controlled risk profile for patient safety, so GMP provenance and correct labeling are central.

Key risks

• GDP mismatch: storage temperature control and handling
• Counterfeit/diversion risk: incorrect supply chain nodes
• NDC/strength mismatch: sourcing error between package sizes or strengths
• Lot release delays: constraints from manufacturing bottlenecks

What generic or biosimilar supplier threats exist for SAMSCA?

Short answer: SAMSCA is a small-molecule branded drug (not a biologic). The relevant threat is generic oral tolvaptan tablets, not biosimilars.

What that means for “suppliers”

• If generics enter, suppliers diversify through ANDA generic manufacturers and their respective packaging networks.
• Until generic approvals occur at scale, supply continuity is dominated by the branded manufacturing ecosystem.

Key Takeaways

• “Suppliers for SAMSCA” usually means wholesaler/distributor nodes for procurement and manufacturing/packaging sites for compliance.
• Accurate supplier identification requires NDC- and lot-level verification using the labeled manufacturer/packager and COA documentation.
• API suppliers are typically located via DMF and FDA establishment listings; finished-dose and packaging suppliers are mapped via NDA-approved manufacturing and packaging site data.

FAQs

1. How do I verify the manufacturing site for SAMSCA using NDC and lot numbers?
   Use the NDC-labeled manufacturer/packager on the bottle/carton and match the lot number to the COA and receiving documentation.

2. Are there multiple API sources for tolvaptan used in SAMSCA commercial supply?
   Branded small-molecule supply chains commonly use more than one registered API source or backup synthesis routes, which show up in FDA establishment/DMF references.

3. What role do contract manufacturers play in SAMSCA tablet production?
   Finished-dose and packaging are often handled by registered contract manufacturing sites that are listed as manufacturers or packagers of record.

4. What changes supplier eligibility criteria for SAMSCA procurement (hospital vs retail)?
   Hospital purchasing typically routes through authorized wholesalers aligned to institutional contracts, while retail channels depend on standard wholesale distribution and specialty fulfillment rules.

5. Do generic tolvaptan products change the supplier landscape for SAMSCA?
   Yes. Generic entry shifts supply toward ANDA manufacturers and their packaging networks once approved products scale.

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Drug Establishments and APIs (registration and listing resources). FDA.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA.